Related Experiment Video
Updated: Jan 2, 2026
A Novel Method to Determine the Longitudinal Antibacterial Activity of Drug-Eluting Materials
Published on: March 3, 2023
Understanding the Activity of Antibiotics in Cerebrospinal Fluid in vitro
Peter Matzneller1, Angela Burian, Markus Zeitlinger
1Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.
Background:
In vitro studies suggest that antimicrobial activity of antibiotics meant to treat central nervous system infections such as meningitis or ventriculitis may be altered by cerebrospinal fluid (CSF). This could explain the reason behind the often observed discrepancies between the activity of antibiotics determined in artificial growth media in vitro, and their sometimes reduced clinical efficacy in CSF in vivo. If conducted in CSF, in vitro microbiological investigations might predict the ability of antibiotic drugs to treat CSF infections better than experiments in artificial growth media. In addition, they are less expensive, critical and time consuming than animal studies, and might potentially be appreciated in drug development as a rapid and cost-effective means to gain valuable information on drugs meant to treat infections residing in CSF.
Summary:
Data from microbiological in vitro experiments performed in CSF were compiled for fosfomycin, rifampicin, cefepime, cefotaxime, ceftriaxone, ciprofloxacin, gentamicin and vancomycin. Where possible, correlations between in vitro data and evidence from in vivo studies were established.
Key Messages:
As discussed in the text, no clear correlations between in vitro studies in CSF and clinical outcomes could be identified. Methodological recommendations derived from the collected studies are summarized in order to optimize future research on the topic.
Insights
Antibiotic activity in cerebrospinal fluid (CSF) may differ from artificial media. In vitro studies using CSF could better predict antibiotic efficacy for central nervous system infections like meningitis, offering a cost-effective approach.
Area of Science:
- Pharmacology
- Infectious Diseases
- Microbiology
Background:
- Antibiotic efficacy in treating central nervous system (CNS) infections like meningitis can be inconsistent.
- Cerebrospinal fluid (CSF) may alter the antimicrobial activity of antibiotics compared to standard artificial growth media.
- Discrepancies between in vitro antibiotic activity and in vivo clinical efficacy are often observed.
Purpose of the Study:
- To evaluate the utility of in vitro microbiological investigations conducted in CSF for predicting antibiotic efficacy in CNS infections.
- To explore the potential of CSF-based in vitro studies as a cost-effective alternative to animal models in drug development for CNS infections.
Main Methods:
- Compilation of data from existing in vitro microbiological experiments performed in CSF.
- Inclusion of data for specific antibiotics: fosfomycin, rifampicin, cefepime, cefotaxime, ceftriaxone, ciprofloxacin, gentamicin, and vancomycin.
- Attempted correlation of in vitro CSF data with available in vivo study evidence.
Main Results:
- Data from in vitro studies using CSF were compiled for several key antibiotics.
- Efforts were made to correlate these in vitro findings with in vivo evidence where possible.
- No clear correlations between in vitro studies in CSF and clinical outcomes were identified.
Conclusions:
- In vitro studies conducted in CSF did not show clear correlations with clinical outcomes for the evaluated antibiotics.
- Methodological recommendations for future research optimizing in vitro CSF studies are summarized.
- Further research is needed to refine in vitro models for predicting antibiotic performance in CNS infections.
More Related Videos
07:42Deferred Growth Inhibition Assay to Quantify the Effect of Bacteria-derived Antimicrobials on Competition
Published on: September 3, 2016
07:46Use of Artificial Sputum Medium to Test Antibiotic Efficacy Against Pseudomonas aeruginosa in Conditions More Relevant to the Cystic Fibrosis Lung
Published on: June 5, 2012
